Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

An orally first-generation EGFR inhibitior.

An orally available, irreversible, third-generation，mutant-selective epidermal growth factor receptor（EGFR）inhibitor. Befotertinib combine with icotinib means that both drugs will be given together until disease progression or meet the discontinuation criteria.